Cancer Genetics jumps over two-fold on unit's merger with biotech start-up

Vyant Bio

24/08/2020 17:18

** Diagnostics co's shares  CGIX.O  more than double in
value to $7.33 
    ** Biotech firm Stemonix will merge with a newly formed unit
of CGIX in an all-stock deal  urn:newsml:reuters.com:*:nGNX9kL2Ph
    ** CGIX will acquire all of Stemonix's outstanding capital
stock for about 78% of its outstanding common stock, and
Stemonix will retain its name
    ** CGIX stock among most actively traded across U.S.
exchanges
    ** Shares up ~29% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))